Latest Ratios: P/E Ratio -0.1x · EV/EBITDA N/A · ROE N/A. (1995–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $696556 | $3M | $34M | $60M | $97M | $286M | — | — | — | — | — |
| Enterprise Value | $2M | $3M | $32M | $59M | $97M | $286M | — | — | — | — | — |
| P/E Ratio → | -0.10 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | — | — | 33.18 | 16.42 | 13.98 | 28.75 | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -236.0% | -94.5% | -42.2% | -102.9% | — | — | -507.3% | -122.3% | -238.8% |
| ROA | -252.3% | -252.3% | -176.0% | -80.9% | -37.2% | -75.8% | -296.1% | -227.5% | -206.5% | -91.4% | -138.2% |
| ROIC | — | — | -550.0% | -72.0% | -31.8% | -67.0% | — | — | -1409.5% | -1807.3% | — |
| ROCE | — | — | -243.6% | -85.5% | -41.4% | -79.0% | -1139.0% | — | -458.9% | -128.0% | -184.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 0.05 | 0.03 | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -1.81 | -0.35 | 0.02 | -0.02 | — | — | — | -0.33 | -1.25 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -24.04 | -24.04 | — | -42.04 | -24.87 | -8.33 | -10.37 | -131.31 | -829.39 | -170.27 | -316.81 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.34 | 0.34 | 2.00 | 6.41 | 7.18 | 13.83 | 1.34 | 0.70 | 0.77 | 3.17 | 4.62 |
| Quick Ratio | 0.34 | 0.34 | 2.00 | 6.41 | 7.18 | 13.83 | 1.34 | 0.70 | 0.77 | 3.17 | 4.62 |
| Cash Ratio | 0.32 | 0.32 | 1.95 | 6.19 | 7.12 | 12.97 | 1.02 | 0.67 | 0.68 | 3.00 | 4.53 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | 35.12 | 35.12 | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — |
| Shares Outstanding | — | $2M | $5M | $4M | $4M | $4M | $3M | $3M | $3M | $3M | $1M |
Binary clinical trial failure
As reported in financial statements, PTIX has consistently posted negative ROIC figures, including a -70.8% return in 2024Q1, illustrating that the company is currently destroying shareholder capital as it funds early-stage clinical development without any offsetting revenue generation or operational efficiency gains to date.
The persistent negative return on capital metrics reflect the structural reality of a pre-revenue biotech firm where R&D spending is mandatory but yields no immediate financial return. Investors should monitor whether future clinical milestones can eventually pivot these returns toward positive territory, though current trends suggest a continued reliance on external capital to bridge the gap.
Based on 2025Q4 reported figures, the current ratio has compressed to 0.34, indicating that the firm's current liabilities significantly outweigh its liquid assets, which leaves the company with a minimal safety margin to navigate unexpected clinical trial costs or potential regulatory delays in the near term.
The rapid decline in the current ratio from 6.41 in 2023Q4 to 0.34 in 2025Q4 highlights a severe deterioration in the company's ability to cover short-term obligations. This liquidity profile suggests that the firm is highly vulnerable to capital market volatility and may require immediate dilutive financing to maintain operational continuity.
According to recent SEC filings, the company's DPO has shown extreme volatility, reaching 13,630 days in 2025Q3, which suggests that the firm is managing its cash outflows through significant delays in vendor payments rather than through standardized operational efficiency or optimized working capital cycles.
This extreme DPO metric is likely a symptom of cash preservation efforts rather than a reflection of supplier leverage. Such erratic working capital patterns warrant further investigation, as they may indicate underlying stress in the company's relationships with its clinical research partners and service providers.
Investors frequently misapply P/E and EV/EBITDA ratios to PTIX, which obscures the firm's true risk profile by ignoring the fact that these metrics are fundamentally meaningless for a pre-revenue entity that lacks any positive earnings or operational cash flow to support traditional valuation modeling.
Instead of relying on earnings-based multiples, analysts should focus on the cash burn rate and the probability-weighted net present value of the PT00114 pipeline. Using traditional valuation ratios for this business model risks creating a false sense of precision in a situation where the primary driver of value is binary clinical success.
Includes 30+ ratios · 29 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PTIX stock.
Protagenic Therapeutics, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
Based on historical data, Protagenic Therapeutics, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.